Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era

Abstract

Spanish

French

Objective:

To review the clinical trials that have impacted treatment standards of multiple myeloma (MM).

Data Source:

A PubMed search (1980–June 2008) restricted to English-language publications was conducted using the key words multiple myeloma, clinical trials, targeted therapy, thalidomide, lenalidomide, bortezomib, dexamethasone, melphalan, autologous stem-cell transplantation, and tumor biology. Abstracts emanating from the meetings of the American Society of Clinical Oncology and American Society of Hematology from June 2002 to June 2008 were also reviewed.

Data Synthesis:

Although hematopoietic stem-cell transplantation has improved the response rate and duration of overall survival, MM remains an incurable disease. However, focused research aimed at the molecular basis of the disease has led to a number of new treatment strategies. Evidence from clinical trials indicates that each of the 3 novel agents, thalidomide, lenalidomide, and bortezomib, is remarkably effective as first-line therapy. The data also suggest that clinicians may need to reevaluate the role of stem-cell transplantation in the disease.

Conclusions:

Thalidomide, lenalidomide, or bortezomib in combination with dexamethasone have replaced traditional chemotherapy such as melphalan, doxorubicin, and vincristine as initial therapy of patients with MM who are eligible for stem-cell transplantation. Furthermore, these novel drugs can be incorporated into regimens used to treat transplant-ineligible patients or those with relapsing disease.

Keywords

autologous stem-cell transplantation bortezomib dexamethasone lenalidomide melphalan multiple myeloma thalidomide

Get full access to this article

View all access options for this article.

References

Kyle

, Rajkumar

. Plasma cell disorders. In: Goldman

, Ausiello

, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia: WB Saunders, 2004:1184–95.

Jemal

, Siegel

, Ward

. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.

Attal

, Harousseau

, Stoppa

. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–7.

Child

, Morgan

, Davies

. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–83.

Singhal

, Mehta

, Desikan

. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–71.

Rajkumar

, Blood

, Vesole

. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–6.

Rajkumar

, Hayman

, Lacy

. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050–3.

Rajkumar

Jacobus

, Callander

. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group (abstract 8504). J Clin Oncol 2008;26:455s.

Jagannath

, Durie

, Wolf

. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776–83.

10.

Seidl

, Kaufmann

, Drach

New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557–64.

11.

Rajkumar

, Mesa

, Fonseca

. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210–6.

12.

Giuliani

, Colla

, Rizzoli

Angiogenic switch in multiple myeloma. Hematology 2004;9:377–81.

13.

Tricot

Multiple myeloma and other plasma cell disorders. In: Hoffman

, Benz

, Shattil

., eds. Hematology: basic principles and practice. 4th ed. Philadelphia, PA: Churchill Livingstone, 2005:1501–35.

14.

Mundy

. Myeloma bone disease. Eur J Cancer 1998;34:246–51.

15.

Durie

, Salmon

. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–54.

16.

Greipp

, San Miguel

, Durie

. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20.

17.

Chng

, Fonseca

Genomics in multiple myeloma: biology and clinical implications. Pharmacogenomics 2005;6:563–73.

18.

Bergsagel

, Kuehl

. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611–22.

19.

Avet-Loiseau

, Attal

, Moreau

. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–95.

20.

Avet-Loiseau

, Munshi

, Li

. High-resolution genomic profiles identify novel genes and/or chromosomal regions with prognostic and oncogenic significance in myeloma patients (abstract 657). Blood 2007;110:202a.

21.

Gertz

, Lacy

, Dispenzieri

. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–40.

22.

Shaughnessy

Jr , Zhan

, Burington

. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–84.

23.

Rajkumar

, Hayman

. Controversies surrounding the initial treatment of multiple myeloma. In: Govindan

, ed. American Society of Clinical Oncology educational book. 44th Annual Meeting. Alexandria, VA: American Society of Clinical Oncology, 2008:369–74.

24.

Hjorth

, Hellquist

, Holmberg

, Magnusson

, Rodjer

, Westin

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: a randomized study. Eur J Haematol 1993;50:95–102.

25.

Anderson

, Alsina

, Bensinger

. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:118–47.

26.

Rajkumar

, Gertz

, Lacy

. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775–9.

27.

Palumbo

, Bringhen

, Petrucci

. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052–7.

28.

Barlogie

, Kyle

, Anderson

. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929–36.

29.

Blade

, Rosinol

, Sureda

. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755–9.

30.

Lazarus

, Phillips

, Herzig

. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol 2008;26:2240–3.

31.

Attal

, Harousseau

, Facon

. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495–502.

32.

Bruno

, Rotta

, Patriarca

. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110–20.

33.

Vallet

, Palumbo

, Raje

. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008;49:1238–45.

34.

Palumbo

, Rajkumar

, Dimopoulos

. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–23.

35.

Zonder

, Crowley

, Hussein

. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized double-blinded, placebo-controlled SWOG trial S0232 (abstract 77). Blood 2007;110:32a.

36.

Mazumder

, Kaufman

, Sagar

. Impact of prior lenalidomide treatment on peripheral blood stem cell mobilization in untreated multiple myeloma patients (abstract 3612). Blood 2007;110:1057a.

37.

Mark

, Jayabalan

, Pearse

. Cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in preparation for autologous stem cell transplantation for multiple myeloma (abstract 3024). Blood 2007;110:888a.

38.

Pal

, Kennedy

, Mansour

. Cathepsin G, a potent platelet aggregation activator is upregulated in multiple myeloma patients during treatment with lenalidomide (abstract 2504). Blood 2007;110:738a.

39.

Richardson

, Hideshima

, Anderson

. Bortezomib (PS-431): a novel, first-in-class proteosome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361–9.

40.

Harousseau

, Attal

, Leleu

. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498–505.

41.

Harousseau

, Mathiot

, Attal

. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial (abstract 450). Blood 2007;110:139a.

42.

Oakervee

, Popat

, Curry

. PAD combination therapy (PS-341/bortezomib, doxorubicin, and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755–62.

43.

Cavo

, Patriarca

, Tacchetti

. Bortezomib-thalidomide-dexamethasone (VTD) vs. thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM) (abstract 73). Blood 2007;110:30a.

44.

Breitkreutz

, Raab

, Vallet

. Lenalidomide and bortezomib: targeting osteoclastogenesis, osteoclast survival factors, and bone remodeling markers in multiple myeloma (abstract 1184). Blood 2007;110:359a.

45.

Gregory

, Richards

, Malpas

. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334–42.

46.

Palumbo

, Bringhen

, Caravita

. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825–31.

47.

Facon

, Mary

, Hulin

. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209–18.

48.

Mateos

, Hernandez

. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93:560–5.

49.

San Miguel

, Schlag

, Khuageva

. A phase III study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma (abstract 76). Blood 2007;110:31a.

50.

Richardson

, Sonneveld

, Schuster

. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.

51.

Richardson

, Barlogie

, Berenson

. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316–9.

52.

Orlowski

, Nagler

, Sonneveld

. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–901.

53.

Dimopoulos

, Spencer

, Attal

. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.

54.

Weber

, Chen

, Niesvizky

. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–42.

55.

Lehmann

, Jean

, Zabelina

. Lenalidomide after allogeneic stem cell transplantation in multiple myeloma (abstract 4840). Blood 2007;110:284b.

56.

Minnema

, van der Veer

, Aarts

. Lenalidomide is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+FOXP3+ T cells (abstract 2722). Blood 2007;110:799a.

57.

Rajkumar

, Fonseca

, Dispenzieri

. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000;75:897–901.

58.

Lee

, Barlogie

, Munshi

. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732–9.

59.

Kyle

, Yee

, Somerfield

. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464–72.

60.

Adamietz

, Schober

, Schulte

RWM

. Palliative radiotherapy in plasma cell myeloma. Radiother Oncol 1991;20:111–6.

61.

Dudeny

, Lieberman

, Reinhardt

M-K

, Hussein

Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002;20:2382–7.

62.

Gagel

. Endocrine manifestations of tumors: “ectopic” hormone production. In: Goldman

, Ausiello

, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia: WB Saunders, 2004:1120–4.

63.

Zarkovic

, Kwaan

. Correction of hyperviscosity by apheresis. Semin Thromb Hemost 2003;29:535–42.

64.

Katodritou

, Zervas

, Terpos

, Brugnara

Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia. Br J Haematol 2008;142:3–10.

65.

Chapel

, Lee

, Hargreaves

, Pamphilon

, Prentice

. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994;343:1059–63.

66.

Pagano

, Fianchi

, Mele

. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002;117:379–86.

67.

Chanan-Khan

, Sonneveld

, Schuster

. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784–90.

68.

Weber

, Rankin

, Gavino

, Delasalle

, Alexanian

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16–9.